Othmar Knoll

interim-management, European market research, strategy development & implementation, international product-launch Europe & Germany (f.e. Qutenza­ - Astellas, patch to manage peripheral neuropathic pain). medico-marketing, medical-education (f.e. Sycrest - Lundbeck, anti-psychotic - bipolar disorder) medical diagnostics, med-tech devices(f.e. Meridox company). pharmacist scientific education (GFI Fortbildungskolleg). in- & out-licensing.

Urology: product-management of Alna (tamsulosin) - dominant market-leadership shared with Yamanouchi, end of life-cycle scenario-management. Urogynecology: co-promotion of Yentreve (stress-urinary-incontinence / duloxetin) in alliance with Eli Lilly Germany. setting-up of a joint-operation-team (both companies with equal power & effort) reg. marketing, market-research, sales-training preparation, kickoff & launch. Together with the Eli Lilly colleague team-leader. Development of complex joint-operation to

Astellas was Yamanouchi at this time; direct reporting to the general manager; full marketing responsibility for the actively marketed product Omnic (tamsulosin - indication benign prostatic hyperplasia); achieving clear market leadership in this segment making Omnic the key product (55mio€) of the German subsidiary, steady & significant growth throughout the life-cycle; recruiting & liaison of KOLs, proactively maintaining the scientific positive tension, building up excellent relationship to urological

preparation & successful launch of the OTC "CM3" (medical EU product, obesity, adiposity). conception & development of TV commercials at launch. Development of promotional programs for different communication platforms: f.e. patients, POS in pharmacy, medical doctors offices

development of a new corporate marketing strategy for the compounds & ingredients delivered to the processing industry.

responsibility all company products: dermatology (Rx & OTC, market leader in segments), gynecology, wide range of Rx-generics, multiple product launches, new business development in eastern European countries, contract & licence management in & out. co-promotion dermosteroids with GlaxoWellcome, co-promotion Fumaderm (TM) with Fumedica (leading antipsoriatic drug), co-marketing with Medice. development of a cfc-free universal device for inhalative drug-delivery (asthma, COPD) jointly with Mundipharma GmbH a

therapeutic drug monitoring (EMIT-range) assays on proprietary lab instruments as well as on co-op partners instruments (Roche Diagnostics) and on third-party instruments (IL, Beckman a.o.); middle and north European responsibility for scientific & commercial launch of assays for TDM in organ transplantation (i.a. peer support & accounting, drafting scientific papers, scientific statistical analysis). Headquarter support in improving assay quality. microbiological assays (cultural methods and automated immu

core products: Augmentin, Betabactyl & Staphylex

immunoassay diagnostics; sophisticated lab instrumentation, viral diseases (HIV, hepatitis a. o.), bacterial diseases, endocrinology, oncology, marketing: sales field support, key accounting, medical education lectures by recruited opinion leaders and myself, first launch (marketing & sales) of a new instrument in a restricted test market in Germany (IMX)